SPARK NS Ignites Hope with $18M for Autism, Parkinson's Research

MENLO PARK, Calif. – February 25, 2026 – Nonprofit translational research organization SPARK NS announced today it has selected nine new projects for its 2026 cohort, committing up to $18 million in new funding to accelerate the development of treatments for autism and Parkinson’s disease. The international projects, led by top academics in the US, UK, and Europe, will join an expanding portfolio aimed at bridging the perilous gap between laboratory discovery and clinical application.

This latest investment brings the organization's total commitment to $44 million across 22 active projects. Founded in 2023, SPARK NS is tackling the notoriously difficult field of neuroscience drug development not just with capital, but with a unique, hands-on model designed to shepherd promising academic ideas through the so-called “valley of death,” where most early-stage research falters.

Beyond the Grant: A New Model for Translational Science

For most academic researchers, securing a grant is only the first hurdle. The path from a promising discovery to a patient-ready therapeutic is fraught with challenges that go far beyond basic science. Industry data reveals a stark reality: the attrition rate for new drugs entering human trials can be as high as 97%, with neuroscience being one of the most challenging fields.

SPARK NS aims to rewrite this narrative with what it calls an “unconventional and proven model.” Unlike traditional funding bodies that provide a grant and await a report, this program immerses its researchers in a comprehensive development ecosystem. Each of the nine new projects is eligible for up to $2 million in milestone-based funding over two years. This means capital is released incrementally as research teams achieve specific, pre-agreed-upon goals, ensuring accountability and a laser focus on progress.

“As an academic with a potential therapeutic I learned years ago that drug development is difficult, takes a long time, and is very expensive,” said Daria Mochly-Rosen, PhD, a SPARK NS Board Director and its Chief Science and Education Advisor. “I also realized that most academic researchers lack the expertise and know-how to overcome the many obstacles on the path to commercialization of even the most promising discoveries. At SPARK NS, we provide funding. We also bring a high level of support and accountability to the process that most academic researchers have never experienced.”

This support extends far beyond the financial. The organization provides research teams with access to a network of over 90 industry expert advisors. These veterans of the pharmaceutical and biotech worlds offer guidance on everything from medicinal chemistry and preclinical development to complex patent strategies and regulatory affairs—knowledge typically siloed within corporate R&D departments and inaccessible to university labs.

A 50% Success Rate in a High-Stakes Field

The organization’s approach is backed by a bold claim: a 50% success rate at guiding discoveries from the lab to the clinic. This figure, supported by a 2024 publication in the peer-reviewed journal Nature Biotechnology, stands in stark contrast to industry norms.

It is crucial, however, to understand the definition of “success” in this context. For SPARK NS, success means advancing a project to the point where it is ready for clinical trials or can be licensed by a commercial partner for further development. While not a guarantee of an approved drug, reaching this stage is a monumental achievement in translational science. Given that many academic discoveries never even approach this phase, a 50% success rate in de-risking projects for clinical entry represents a significant improvement over the status quo.

This model was honed over two decades at Stanford University before being spun out into the independent nonprofit, demonstrating a long-term, evidence-based approach to solving the translational research puzzle.

A Global Brain Trust Targeting Neurological Disease

The 2026 cohort underscores the global and collaborative nature of modern science. The nine selected principal investigators represent a transatlantic alliance of leading institutions, from KU Leuven in Belgium and Ulm University in Germany to Imperial College London in the UK and Stanford, UCSF, and Mount Sinai in the US.

Their projects target the underlying biology of autism and Parkinson's disease from multiple innovative angles. Research includes:

• Targeting Neuroinflammation: Dr. Veerle Baekelandt at KU Leuven and Dr. Pamela M. England at UCSF are independently pursuing therapies aimed at quelling the damaging inflammation in the brain associated with Parkinson's disease.
• Gene-based and RNA-based Therapies: Dr. Tobias M. Boeckers at Ulm University is developing a therapeutic for a specific genetic form of autism (Shank3-related), while Dr. Joseph D. Buxbaum at Icahn School of Medicine at Mount Sinai is working on small molecules that target RNA to treat autism.
• Novel Genetic Approaches: Dr. Michael Johnson at Imperial College London is using a human genetics-driven approach for disease modification in Parkinson's, and Dr. Špela Miroševič of the CTNNB1 Foundation is pioneering a gene therapy for a rare form of autism.

Other projects focus on lipid metabolism, GABAergic transmission, and enhancing the cell's natural waste-clearing processes—all cutting-edge strategies with the potential to fundamentally alter the course of these debilitating conditions.

Filling a Critical Gap in a Challenging Funding Landscape

The infusion of capital and expertise from SPARK NS comes at a critical time. In recent years, federal funding for neuroscience research has faced significant constraints. The National Institutes of Health (NIH), the primary engine of biomedical research in the US, awarded approximately 37% fewer new neuroscience grants in 2025 compared to the prior nine-year average, creating a precarious environment for innovation.

While large disease-specific foundations like the Michael J. Fox Foundation for Parkinson's Research remain powerhouses in the field, SPARK NS is carving out a vital niche. Its focus is not just on funding science, but on building the bridge between the academic world and the commercial one—a gap that philanthropy and venture capital are increasingly trying to fill.

By providing a structured pathway, expert mentorship, and milestone-driven funding, the organization offers a lifeline to high-risk, high-reward projects that might otherwise languish in academic labs. As the program expands, it signals a growing recognition that solving the most complex brain disorders requires not only brilliant science but also a smarter, more collaborative approach to bringing those discoveries to the patients who need them.

With the 2026 cohort now underway, SPARK NS is already looking ahead, with a call for proposals for its 2027 cohort slated for release in March 2026, continuing its mission to turn academic promise into clinical reality.